ECM
GOSS icon

Endurant Capital Management’s Gossamer Bio GOSS Stock Holding History

Endurant Capital Management’s Portfolio GOSS Stock Details GOSS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-68,710
Closed -$596K – 63
2022
Q1 		$596K Sell
68,710
-44,950
-40% -$433K 0.16% 60
2021
Q4 		$1.28M Buy
+113,660
New +$1.35M 0.31% 52

Other funds holding GOSS

HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Endurant Capital Management's GOSS Position: Q2 2022 in Review

Endurant Capital Management sold out of Gossamer Bio (GOSS) in Q2 2022, closing a stake of 68,710 shares — an estimated $596K sold.

Endurant Capital Management first reported a position in GOSS in Q4 2021 and held it in 2 quarters. The position peaked at $1.28M in Q4 2021. 129 funds tracked by Wall St. Rank hold GOSS as of Q2 2022.

  • Endurant Capital Management reported no remaining Gossamer Bio position as of Q2 2022 after selling out during the quarter.
  • Endurant Capital Management sold 68,710 Gossamer Bio shares in Q2 2022, an estimated $596K.
  • Endurant Capital Management first reported a position in Gossamer Bio in Q4 2021 and held it in 2 quarters.
  • Endurant Capital Management's Gossamer Bio position peaked at $1.28M in Q4 2021.
  • 129 funds tracked by Wall St. Rank held Gossamer Bio as of Q2 2022.

Based on Endurant Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.